- All patients with HER-2 positive breast cancer patients:
- Who require systemic therapy should complete one year of HER2-targeted therapy:
- Including those who achieve pathologic complete response after neoadjuvant chemotherapy
- One could also consider continuing adjuvant pertuzumab in addition to trastuzumab:
- Based on results from the phase III Aphinity trial:
- Although patients who received neoadjuvant chemotherapy were not included in this trial
- Based on results from the phase III Aphinity trial:
- For patients who have residual disease and do not achieve complete pathologic response at the time of surgery:
- Completion of one year of T-DM1 decreased the risk of recurrence of invasive breast cancer or death by 50% than with trastuzumab alone:
- Based on results from KATHERINE trial:
- The estimated percentage of patients who were free of invasive disease at 3 years was:
- 88.3% in the T-DM1 group and 77.0% in the trastuzumab group
- The estimated percentage of patients who were free of invasive disease at 3 years was:
- Based on results from KATHERINE trial:
- Completion of one year of T-DM1 decreased the risk of recurrence of invasive breast cancer or death by 50% than with trastuzumab alone:
- Who require systemic therapy should complete one year of HER2-targeted therapy:
- References:
- von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer N Engl J Med. 2017;377(2):122-131.
- von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628.
#Arrangoiz #CancerSurgeon #BreastSurgeon #BreastCancer #CASO #CenterforAdvancedSurgicalOncology
Rodrigo Arrangoiz MS, MD, FACS, FSSO 